Al Hammadi's unit inks deal with NUPCO, Sanofi to localize insulin industry

Al Hammadi Holding’s 35%-owned subsidiary Sudair Pharmaceuticals Co. signed a seven-year agreement with the National Unified Procurement Co. (NUPCO) and Sanofi to localize the insulin industry in Saudi Arabia.

In a statement to Tadawul today, Oct. 30, Al Hammadi pointed out that the seven-year agreement includes a commitment to purchase insulin products.

The cost of the project will be determined later.

Aimed at establishing a specialized factory in the Kingdom to manufacture and package insulin, this agreement was conclude as a strategic partnership to mitigate the burden resulting from importing medicines, enhance access to high-quality insulin for diabetics, and contribute to making Saudi Arabia a regional hub for medicine manufacturing biomedicines, in line with Vision 2030.

Sanofi will transfer its technological expertise and global knowledge in the field of biological technologies to Sudair Pharma, with the purpose of achieving 100% localized insulin production, in order to contribute to raising the local content in the Kingdom towards localizing basic pharmaceutical industries, enhancing economic diversification, and placing Saudi Arabia in an advanced rank within life science fields.

The relevant financial impact is expected to reflect on the company’s H1 2024 results, the statement added, noting that there are no related parties to the agreement.